U.S. markets close in 3 hours 45 minutes
  • S&P 500

    4,144.85
    -0.34 (-0.01%)
     
  • Dow 30

    32,842.94
    +39.47 (+0.12%)
     
  • Nasdaq

    12,669.16
    +11.60 (+0.09%)
     
  • Russell 2000

    1,945.03
    +23.21 (+1.21%)
     
  • Crude Oil

    90.37
    +1.36 (+1.53%)
     
  • Gold

    1,802.80
    +11.60 (+0.65%)
     
  • Silver

    20.65
    +0.80 (+4.05%)
     
  • EUR/USD

    1.0213
    +0.0026 (+0.26%)
     
  • 10-Yr Bond

    2.7770
    -0.0630 (-2.22%)
     
  • GBP/USD

    1.2088
    +0.0018 (+0.15%)
     
  • USD/JPY

    134.7140
    -0.2560 (-0.19%)
     
  • BTC-USD

    23,945.65
    +907.05 (+3.94%)
     
  • CMC Crypto 200

    557.77
    +14.89 (+2.74%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Biogen profit tumbles 71% on rising competition to multiple sclerosis drug

In this article:
  • Oops!
    Something went wrong.
    Please try again later.

July 22 (Reuters) - Biogen Inc on Thursday reported a 70.9% fall in quarterly profit as competition intensifies for multiple sclerosis drug Tecfidera, once the company's flagship treatment.

The company, which is facing some hesitancy from hospitals and insurers over its recently approved Alzheimer's drug Aduhelm, earned $448.5 million, or $2.99 per share, in the second quarter ended June 30, from $1.54 billion, or $9.59 per share, a year earlier. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)